Drugs / ORG 34517
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT06712602 | Feb 2025 → Jul 2028 expected | alcohol-related disorders | Pop Test Oncology LLC | Recruiting | No outcome recorded |
| Phase 1 | NCT04331288 | Nov 2021 → Oct 2023 | alcohol dependence | Pop Test Oncology LLC | Completed | No outcome recorded |
| Phase 1 | NCT03548714 | Sep 2018 → Jul 2019 | alcohol dependence | Pop Test Oncology LLC | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT07187011 | Apr 2026 → Mar 2029 expected | post-traumatic stress disorder | San Diego Veterans Healthcare System | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT00844922 | Sep 2005 → Jun 2006 | depressive disorder, psychotic disorder | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT00226278 | Sep 2004 → Nov 2005 | major depressive disorder, psychotic disorder | Weill Medical College of Cornell University | Completed | No outcome recorded |
| Phase 2 | NCT00212797 | Jul 2004 → Jul 2006 | depressive disorder, psychotic disorder | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Org 34517 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00212797 ↗ |
| Known as | Formerly ORG34517 | “Formerly ORG34517” NCT04331288 ↗1“Formerly ORG34517” NCT03548714 ↗ |
| Known as | PT150 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07187011 ↗ |
| Known as | SCH 900636 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00844922 ↗ |
| Action | Inhibit | “The primary purpose of this study is to determine whether subjects with psychotic major depression benefit from adjunctive treatment with GR antagonist Org 34517.” NCT00212797 ↗1“Glucocorticoid receptor antagonist” CHEMBL3545391 ↗ |
| Modality | Small molecule | — CHEMBL3545391 ↗ |
| Route | Oral | “PT150 (900 mg/day) was administered orally to all participants for five days.” PMID 33972573 ↗ May 2021 |
| Target | NR3C1 | “Glucocorticoid receptor antagonist” CHEMBL3545391 ↗ |